Roth Capital Cuts Price Target on Curis (CRIS) Following 2Q Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
FBR Capital Starts Curis (CRIS) at Outperform
August 10, 2015 5:44 PM EDTFBR Capital initiates coverage on Curis (NASDAQ: CRIS) with a Outperform rating and a price target of $6.00.
Analyst Christopher S. James, M.D. commented, " Curis is a biotech company developing oral small molecule drugs targeting critical pathways in cancer that are either discovered internally or acquired through... More
Curis (CRIS) Reports In-Line Q2 EPS
August 6, 2015 7:07 AM EDTCuris (NASDAQ: CRIS) reported Q2 EPS of ($0.06), in-line with the analyst estimate of ($0.06). Revenue for the quarter came in at $2.1 million versus the consensus estimate of $3.5 million.
For earnings history and earnings-related data on Curis (CRIS) click here.
... More